1.. Introduction
================

Innovative targeted therapeutic strategies aim at developing new molecules with high target affinity and specificity with suitable pharmacokinetic properties for *in vivo* applications. From this optic short non-coding RNAs were revealed to be attractive molecules. In the last decades significant advances have been attained in the knowledge of molecular mechanisms leading to selective inhibition of gene expression and protein function. However, in order to successfully translate RNA-based therapeutics to the clinic several challenges must be addressed, including appropriate stability in biological fluids, high efficiency and specificity of delivery, durable safety and target selectivity.

Several classes of molecules have been characterized with potential applications as RNA therapeutics in the treatment of human diseases. These include ribozymes, RNA decoys, aptamers, small interfering RNA (siRNA) and microRNA (miRNA) \[[@b1-pharmaceuticals-04-01434]\].

The discovery of RNA-mediated interference (RNAi) for gene silencing has provided a powerful tool for loss-of-function studies and therapeutic opportunities \[[@b2-pharmaceuticals-04-01434],[@b3-pharmaceuticals-04-01434]\]. RNA interference is a natural process of gene specific silencing that occurs in organisms ranging from plants to mammals as a defense against viruses. si/miRNAs are formed from longer precursor molecules as short double-stranded RNAs (dsRNAs) of 20--24 base pairs \[[@b4-pharmaceuticals-04-01434]\]. One strand that directs silencing is the *guide* strand while the other strand, named the *passenger*, is degraded. In the cytoplasm, the RNA-induced silencing complex (RISC) drives the *guide* strand of the dsRNA to hybridize with the target mRNA to prevent translation or induce degradation depending on the degree of complementarity \[[@b5-pharmaceuticals-04-01434]\]. Base pairing between siRNAs and their targets generally shows full complementarity whereas, with the exception of the 2--8 bases *seed* region at the 5′ terminus, miRNAs usually show partial complementarity with their targets. miRNAs have the capacity to target multiple genes simultaneously and regulate important biological processes including, transcription, cell cycle, cell growth, proliferation and apoptosis. They have been shown to be involved in the pathogenesis of diverse diseases including cancer, stroke, diabetes, diseases of the liver, kidney, and cardiovascular system as well as neurodegenerative and infectious diseases \[[@b6-pharmaceuticals-04-01434]-[@b8-pharmaceuticals-04-01434]\]. On the other hand siRNAs are the best characterized RNA-based reagents that have been developed for several disease including cancer, kidney, ocular, retinal and metabolic disorders.

As a difference with siRNAs and miRNAs, the function of ribozymes and aptamers doesn\'t involve the formation of the RISC. The hammerhead small ribozymes are nucleolytic oligonucleotides that recognize and excise a given target RNA molecule \[[@b9-pharmaceuticals-04-01434]\]. Aptamers constitutes an emerging attractive class of therapeutic molecules able to tightly bind to specific protein or non-protein targets by folding into complex tertiary structures \[[@b10-pharmaceuticals-04-01434],[@b11-pharmaceuticals-04-01434]\].

Recognition by toll-like receptors (TLRs) in immune cells represents a major obstacle to the use of RNA-based therapeutics. However, immune recognition the immune response of single stranded siRNAs (ss-siRNA) or ds-siRNAs by TLRs can be bypassed by the replacement of only uridines with their 2′-fluoro, 2′-deoxy, or 2′-*O*-methyl modified counterparts without reducing their silencing potency \[[@b12-pharmaceuticals-04-01434]-[@b15-pharmaceuticals-04-01434]\]. In addition, immunogenicity has been found to be either absent or limited when 1,000-fold higher doses of a nucleic acid aptamer than would be required clinically were administered to monkeys \[[@b16-pharmaceuticals-04-01434]\]. This property depends on the fact that antibodies to synthetic oligonucleotides are not generally produced and, in addition, the innate immunity response against non-self RNAs does not hinder aptamer therapy because 2′-modified nucleotides abrogate TLRs responses \[[@b17-pharmaceuticals-04-01434]\].

A major impediment to the clinical development of RNA drugs is the lack of an appropriate and high efficiency *in vivo* delivery strategy to guarantee intracellular target accessibility and specificity of delivery. The use of viral vectors, despite their high efficiency, has been impaired greatly due to the associated mutagenicity or oncogenesis, several host immune responses, and high cost of production. Therefore, non-viral vectors continue to draw significant attention despite their low efficacy.

2.. RNA-Based Therapies
=======================

Currently, the list of oligonucleotides of therapeutic interest is growing rapidly with over one hundred clinical trials and two therapeutic oligonucleotides that have been already approved by U.S. Food and Drug Administration (FDA) and marketed, the Vitravene antisense antiviral and the Macugen RNA-based aptamer. Two classes of therapeutic oligonucleotides have predominantly been developed: siRNA and aptamers, and several of them are currently in clinical trials ([Table 1](#t1-pharmaceuticals-04-01434){ref-type="table"}).

2.1.. siRNAs
------------

Recently, the use of RNAi-based gene silencing has been demonstrated in humans for treatment of several diseases, as discussed in multiple recent reviews \[[@b18-pharmaceuticals-04-01434]\]. We report here only few not exhaustive examples of the possible therapeutic applications.

Various clinical studies have explored the direct tissue delivery of siRNA into the eye for macular degeneration in humans. Among the growth factors implicated in the age-related macular degeneration (AMD) process, the vascular endothelial growth factor (VEGF) has been shown to be a major inducer of choroidal neovascularization \[[@b19-pharmaceuticals-04-01434]\]. Several studies have recently addressed the silencing of VEGF \[[@b20-pharmaceuticals-04-01434],[@b21-pharmaceuticals-04-01434]\] or the VEGF receptor 1 (VEGFR1) \[[@b22-pharmaceuticals-04-01434]\] by RNA interference (RNAi) using either intravitreous/periocular injection of siRNA or using adenovirus backbones to allow stable endogenous transgene expression of short hairpin (sh)RNAs resulting in a potent reduction of VEGF or VEGFR1.

Silencing of gene expression by RNAi has been extensively studied to develop innovative cancer therapeutic strategies. Indeed, many of the siRNAs are in different stages of development for the treatment of different kind of tumors. For examples, among the siRNA therapeutics for the treatment of solid tumors, CALAA-01 and Atu027, targeting the M2 subunit of ribonucleotide reductase and protein kinase N3, respectively, are in Phase I, whereas, FANG against Furin is in Phase II. Further, SPC2996 against BCL-2 is in Phase II for treatment of chronic myeloid leukemia (from <http://ClinicalTrials.gov>). As shown in [Table 1](#t1-pharmaceuticals-04-01434){ref-type="table"}, the number of possible applications of RNAi therapeutics are growing rapidly and now include also viral infections, respiratory, brain, skin and metabolic diseases.

In recent studies, given the strong impact of siRNAs for therapeutic applications, a great effort is focused on the optimization of the efficacy of the siRNAs through relatively minor chemical and structural modifications to canonical siRNA. The final aim is to improve loading of the guide strand into the RNAi machinery and reduce off-target effects and competition with endogenous miRNAs.

The group of Rossi \[[@b23-pharmaceuticals-04-01434]-[@b26-pharmaceuticals-04-01434]\] has reported pioneering studies demonstrating that Dicer substrate interfering RNA (dsiRNA) are more potent than classical synthetic 21-mer siRNAs, showing more robust formation of a high molecular weight complex known to contain Dicer and TRBP (two primary members of the RISC-loading complex).

2.2.. Aptamers
--------------

Aptamers are short single-stranded DNAs or RNAs that like antibodies, bind with high affinity to specific targets by folding into complex tertiary structures. They have some important advantages over antibodies and other protein-based reagents as therapeutics. A number of these advantages stem from the fact that aptamers are generated by an iterative *in vitro* evolution procedure named Systematic Evolution of Ligands by EXponential enrichment (SELEX) avoiding the use of animals or cells. In addition, aptamers can be readily chemically modified to enhance their bioavailability and pharmacokinetics \[[@b27-pharmaceuticals-04-01434]-[@b29-pharmaceuticals-04-01434]\]. Further, as discussed above, another important advantage of RNA aptamers over proteins is the fact that RNA is much less immunogenic than proteins \[[@b16-pharmaceuticals-04-01434]\].

The list of aptamers against important therapeutic targets is growing rapidly and some of them have already entered the clinical pipeline (see [Table 1](#t1-pharmaceuticals-04-01434){ref-type="table"}) for the treatment of different diseases \[[@b30-pharmaceuticals-04-01434]-[@b32-pharmaceuticals-04-01434]\]. The most successful therapeutic application of an aptamer is represented by Macugen (or pegaptanib, marketed by Eyetech Pharmaceuticals/Pfizer), an RNA-aptamer that binds and antagonizes the action of VEGF. The aptamer has been fully approved by the FDA in December 2004 for the treatment of exudative AMD. In order to translate this aptamer into the clinic, it has been chemically modified with 2′-fluoropyrimidines (2′-F-Py), 2′-*O*-Me-purines (2′-*O*-Me-Pu) and polyethylene glycol (PEG) to generate a better therapeutic agent \[[@b33-pharmaceuticals-04-01434],[@b34-pharmaceuticals-04-01434]\].

Many other aptamers, not yet approved by the FDA, are currently in clinical trials. For example other two aptamers, named E10030 and ARC1905, are in Phase II and I of clinical trials for the treatment of AMD, respectively. E10030 is a DNA-aptamer directed against the platelet-derived growth factor-B (PDGF-B) chemical modified with 2′-F-Py and 2′-OMe-Pu and PEG \[[@b35-pharmaceuticals-04-01434]\]; while ARC1905 is a RNA-aptamer targeting the complement component 5 (C5) containing 2′-F-Py and PEG \[[@b36-pharmaceuticals-04-01434],[@b37-pharmaceuticals-04-01434]\].

Furthermore, different aptamers targeting blood-clotting factors seems to be effective anticoagulant agents. The ARC1779 is a DNA-aptamer directed against the A1 domain of von Willebrand factor, currently in phase II clinical trials for the treatment of thrombotic microangiopathies (TMA) \[[@b38-pharmaceuticals-04-01434],[@b39-pharmaceuticals-04-01434]\]; while Nu172 is a chemical unmodified DNA-aptamer directed against thrombin, currently in phase II clinical trials to evaluate its potential use as an anticoagulant during acute coronary artery bypass surgery.

Particularly interesting is REG-1, an aptamer targeting the coagulation factor IXa. This is the first case of a modulator-controlled aptamer able to provide a time-controllable therapy. REG-1 is a two-part therapeutic agent, consisting of an RNA aptamer specific for the coagulation factor IXa (RB006) and a single stranded RNA oligonucleotide complementary to the RB006 aptamer (RB007). Aptamer inhibition of the factor IXa by RB006 is structurally disrupted by administration of the antidote complementary strand RB007. The REG-1 aptamer-antidote therapy has been tested in Phase I and II clinical trials with promising results as an anticoagulation therapy to prevent clot formation during cardiac surgery \[[@b40-pharmaceuticals-04-01434]\].

Moreover, different aptamers for cancer therapy are also in clinical trials. NOX-A12 is an L-RNA spiegelmer directed against the stromal cell-derived factor-1α (SDF-1α), a chemokine which attracts and activates immune and non-immune cells that bind to chemokine receptors CXCR4 and CXCR7. This aptamer is in Phase I clinical trials for the treatment of hematologic tumors. The AS1411 aptamer, instead, showed effectiveness for the treatment of acute myeloid leukaemia (AML) in phase I and II clinical trials. AS1411 is a DNA-aptamer, directed against nucleolin \[[@b41-pharmaceuticals-04-01434]\], a protein often overexpressed on the surface of cancer cells. This DNA aptamer is part of the guanine-rich oligonucleotide class of aptamers that form G-quartets, a structural element that exhibits antiproliferative activity. Nucleolin has many functions, so inhibiting this protein with AS1411 affects a variety of signaling pathways, including NF-κB \[[@b42-pharmaceuticals-04-01434]\] and Bcl-2 \[[@b43-pharmaceuticals-04-01434]\].

Apart from the aptamers mentioned above, many other aptamers are not yet developed in clinic but target molecules of high therapeutic interest thus appearing as excellent drug candidates for a wide range of human pathologies \[[@b30-pharmaceuticals-04-01434]\].

2.3.. miRNAs
------------

Although the clinical development of miRNAs has not yet been realized, they are attractive candidates as prognostic biomarkers and therapeutic targets in different diseases including cardiovascular disease and cancer. In addition, the use of complementary antisense oligonucleotides has been developed for miRNA silencing in research and therapy. Antisense inhibitors act by competing for miRNA binding to the proper sites on target mRNAs and include small synthetic RNAs, antagomir, and modified RNA oligonucleotides, as locked nucleic acid (LNA) \[[@b44-pharmaceuticals-04-01434]\].

Cardiovascular disease is the leading cause of death in industrialized nations. Several miRNAs have been recently implicated in cardiomyocyte hypertrophy, increased fibrosis and apoptosis during heart failure \[[@b45-pharmaceuticals-04-01434]\]. Using mice with induced cardiac hypertrophy it has been recently shown that miR21 is upregulated in hearth fibroblasts, increases the extracellular signal-related kinases (ERKs)-mitogen-activated protein kinase (MAPK) activity and regulates cell survival and growth factor secretion. Cardiac hypertrophy and fibrosis can be attenuated and even prevented by the administration of a specific antagomir that suppresses miR-21 levels and reduces cardiac ERK-MAPK activity \[[@b46-pharmaceuticals-04-01434]\]. On the other hand, has been shown that miR-199a expression is sensitive to low oxygen levels and is rapidly downregulated in cardiac myocytes to undetectable levels, thus rapidly resulting in increased levels of mRNA target, hypoxia-inducible factor (Hif)-1alpha. Conversely, restoring miR-199a levels during hypoxia inhibits Hif-1alpha expression, reduces apoptosis and protects the cells from hypoxic injury \[[@b47-pharmaceuticals-04-01434]\]. Cardiac remodeling can be as well prevented by the administration of an inhibitory antagomir for the cardiac-specific miR-208a thus improving the overall survival of treated rats \[[@b48-pharmaceuticals-04-01434]\]. All together, these studies indicate the potential of RNA-based therapies for cardiovascular diseases.

Expression of several miRNAs has been shown to be deregulated in many cancer types. Further, based on their involvement in basic cellular functions, miRNAs may act as oncogenes (oncomirs) or tumor suppressor as critical players in cell transformation \[[@b49-pharmaceuticals-04-01434]-[@b51-pharmaceuticals-04-01434]\].

For example, it has been demonstrated that the let-7 family contains miRNAs regulating the RAS family of oncogenes \[[@b52-pharmaceuticals-04-01434]\]. Petrocca *et al.* \[[@b53-pharmaceuticals-04-01434]\] showed that the miR-106b-25 cluster plays a key role in gastric cancer interfering with proteins involved both in cell cycle and apoptosis. In other studies, miR-155 was found overexpressed in Hodgkin lymphoma, pediatric Burkitt lymphoma and diffuse large B-cell Lymphoma \[[@b54-pharmaceuticals-04-01434]-[@b56-pharmaceuticals-04-01434]\]; miR-143 and miR-145 were significantly downregulated in colon cancer tissue compared with colonic mucosa \[[@b57-pharmaceuticals-04-01434]\]; miR-21 was overexpressed in many tumors \[[@b49-pharmaceuticals-04-01434]\], including glioblastoma \[[@b58-pharmaceuticals-04-01434]\], cholangiocarcinoma \[[@b59-pharmaceuticals-04-01434]\], multiple myeloma cells \[[@b60-pharmaceuticals-04-01434]\] and breast cancer \[[@b61-pharmaceuticals-04-01434],[@b62-pharmaceuticals-04-01434]\]. Moreover, studies that investigated the expression of the entire microRNAome in various human solid tumors and hematologic malignancies have revealed differences in miRNA expression profiling between neoplastic and normal tissues \[[@b63-pharmaceuticals-04-01434]-[@b66-pharmaceuticals-04-01434]\]. miRNAs play a key role also in tumor metastasis. Indeed, for example miR-139 suppresses metastasis of hepatocellular carcinoma, while miR10-b was found highly expressed in metastatic breast cancer cells \[[@b67-pharmaceuticals-04-01434],[@b68-pharmaceuticals-04-01434]\] even if its clinical utility is still questioned \[[@b69-pharmaceuticals-04-01434]\].

3.. RNA-Based Bioconjugates Molecules for siRNA Delivery
========================================================

Potent sequence selective gene inhibition by siRNA 'targeted' therapeutics promises the ultimate level of specificity, but siRNA therapeutics is hindered by poor intracellular uptake, thus efficient delivery strategies remains the main challenge for their clinical development \[[@b70-pharmaceuticals-04-01434]\].

In this respect a promising application of aptamers is to use them to deliver a variety of secondary reagents, including therapeutic siRNAs, specifically to a targeted cell population ([Table 2](#t2-pharmaceuticals-04-01434){ref-type="table"}) \[[@b71-pharmaceuticals-04-01434],[@b72-pharmaceuticals-04-01434]\].

This means that aptamers function as specific recognition ligands to target cells, which is especially significant given the whole cell-SELEX strategy to target specifically cell surface epitopes \[[@b73-pharmaceuticals-04-01434]\]. Once delivered, the secondary reagents would then impart their therapeutic effect to this subset of cells within the treated individual. Because non-targeted cells would not be exposed to the secondary reagent, the potential for unwanted side-effects such as death of normal cells is substantially reduced.

The cell-SELEX method allows for the generation of aptamers against cell surface targets by replicating the native conformation and glycosylation pattern of the extracellular regions of proteins. Recently, multiple groups have reported selections using living cells as the target to identify receptor-specific aptamers and those that bind to a specific cell type \[[@b73-pharmaceuticals-04-01434],[@b74-pharmaceuticals-04-01434]\]. Some of these aptamers have been used as delivery cargos to target cells giving the cell-type specific expression of cell surface proteins on cell populations of therapeutic value.

In the aptamer-based delivery approach, the last goal is to develop an aptamer to the extracellular portion of such a protein and then use the aptamer to deliver the secondary reagent to the targeted cell population via binding the targeted protein on the surface of the targeted cell type. Because this binding in some cases also results in the endocytosis of the aptamer/secondary reagent complex, this approach can be used to deliver reagents such as siRNAs that depend on delivery to intracellular compartments for their proper function ([Figure 1](#f1-pharmaceuticals-04-01434){ref-type="fig"}).

To date, the best-characterized aptamers for targeted delivery are the two 2′-F-Py-RNA aptamers (A9 and A10) that have been generated against the extracellular domain of the prostate-specific membrane antigen (PSMA) \[[@b75-pharmaceuticals-04-01434]\]. These aptamers bind with high affinity to the acinar epithelial cells of prostate cancer tissue. They have been used to deliver not only siRNA, but also nanoparticles, quantum dots (QDs) and toxins to prostate cancer cells \[[@b73-pharmaceuticals-04-01434]\]. Different approaches in which PSMA-aptamer has been linked to siRNAs have been reported ([Figure 2](#f2-pharmaceuticals-04-01434){ref-type="fig"}).

A first study reports the non-covalent conjugation of siRNA with A9 aptamer via a streptavidin connector \[[@b76-pharmaceuticals-04-01434]\]. The 27mer Dicer substrates targeting laminin A/C and GAPDH genes and the RNA aptamers were chemically conjugated with biotin. Thus, two biotinylated siRNAs and two aptamers were non-covalently assembled via a streptavidin bridge. The resulting conjugates were incubated with PSMA-positive LNCaP cells without any further preparation, and were taken up within 30 min. The inhibition of gene expression was mediated by the aptamers and as efficient as observed with conventional lipid-based reagents.

In the same year, McNamara *et al*. \[[@b77-pharmaceuticals-04-01434]\] described the generation of the anti-PSMA A10 aptamer-siRNA chimeras. The 3′ end of the aptamer was extended to contain the nucleotidic sequence complementary to the antisense strand of siRNA targeting the polo-like kinase 1 (PLK1) and BCL-2 survival genes, and the chimera was formed by annealing the aptamer to the siRNA antisense strand. The resulting chimeras were effective in silencing target genes and inducing cell death specifically in PSMA-positive cancer cells.

In addition, the PSMA-siRNA chimeric molecule has been further modified for *in vivo* application \[[@b78-pharmaceuticals-04-01434]\]. The aptamer portion of the chimera was truncated, and the sense and antisense strands of the siRNA portion were swapped. A two-nucleotide 3′-overhang and a PEG tail were added to the chimera. The modified chimera was able to inhibit prostate cancer xenograft growth when administrated systemically.

To date several groups have adapted the covalent assembly approach to aptamer-mediated siRNA delivery \[[@b72-pharmaceuticals-04-01434]\]. In these studies, the anti-PSMA A10 aptamer has been conjugated to siRNAs against eukaryotic elongation factor (EEF)2 \[[@b79-pharmaceuticals-04-01434]\] and two key components of the nonsense-mediated mRNA decoy (NMD) \[[@b80-pharmaceuticals-04-01434]\]. In addition, since short hairpin RNAs (shRNAs), like miRNA precursors are better substrates for Dicer, Ni *et al*. \[[@b81-pharmaceuticals-04-01434]\] linked a shRNA against the DNA-activated protein kinase (DNA-PK) to a truncated A10 aptamer (A10-3) generating a single intact nuclease-stabilized 2′ fluoro-modified pyrimidine molecule. The 3′-terminus of the A10 aptamer was conjugated to the passenger (sense) strand of the siRNA, followed by a 10-mer loop sequence and then by the guide or silencing (antisense) strand of the siRNA.

Rossi and colleagues have extensively characterized the HIV glycoprotein gp120 as a target for aptamer-mediated siRNA delivery \[[@b82-pharmaceuticals-04-01434]-[@b84-pharmaceuticals-04-01434]\]. In these studies, an inhibitory RNA aptamer targeting the HIV envelope protein gp 120, has been used to deliver attached anti-HIV *tat/rev* siRNAs into HIV infected cells via binding to envelope expressed on the cell surface, resulting in internalization of the aptamer and delivery of a dicer substrate siRNA to RISC. *In vivo* delivery of the aptamer and aptamer-siRNA conjugates into a humanized mouse model for HIV infection suppressed HIV replication and completely protected T-cells from HIV mediated T-cell killing.

With the development of the conjugation strategies, the list of aptamers against surface epitopes that are being used as delivery agents is growing rapidly and now includes those against PTK7 \[[@b85-pharmaceuticals-04-01434],[@b86-pharmaceuticals-04-01434]\], nucleolin \[[@b87-pharmaceuticals-04-01434]\], mucin 1 \[[@b88-pharmaceuticals-04-01434],[@b89-pharmaceuticals-04-01434]\], and EGFR \[[@b90-pharmaceuticals-04-01434]\] the have been used to deliver not only siRNA, but also nanoparticles, quantum dots (QDs), toxin and chemiotherapeutics to target cells (see [Table 2](#t2-pharmaceuticals-04-01434){ref-type="table"}).

4.. Market and Perspectives
===========================

Even if only one nucleic acid aptamer has been approved and is on the market, aptamers hold an extraordinary potential in drug development and it is plausible that the global interest for their development will increase in the next few years. Accordingly, a new technical market research report, from BCC Research \[[@b91-pharmaceuticals-04-01434]\], estimated that the global aptamer market value of \$236 million in 2010 will grow to nearly \$1.9 billion in 2014, for a 4-year compound annual growth rate of 67.5%.

To date, Archemix Corp. is a leading biopharmaceutical company in the development of aptamers as therapeutics. It is the owner of the aptamer technology patent and it collaborates with other pharmaceutical companies (Regado, Antisoma, ARCA Biopharma and Ophthotech) to develop and commercialize a pipeline of partnered aptamers in the cardiovascular disease, hematology and oncology areas.

Moreover, the development of aptamers as delivery agents for therapeutic RNAs can have a considerable impact on aptamer market in the near future. Indeed, intracellular delivery has been a key challenge for RNA modalities and the potential of bringing together the properties of aptamers and microRNA therapeutics will allow to overcome this limitation and open further potential for RNA-based therapeutics.

Recently Archemix Corp. started a collaboration with miRagen Therapeutics Inc., a biopharmaceutical company focused on developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, for the development of conjugated aptamer-microRNA molecules capable of intracellular delivery and subsequent microRNA targeting. Combining aptamers and microRNA therapeutics has the potential to solve the intracellular delivery challenge for certain RNA-based therapeutic approaches. In this perspective, even if aptamer-miRNA chimeras have not been already described in literature, it is plausible that the approaches discussed in this review for aptamer-siRNA conjugation could be as well adapted to generate aptamer-miRNA molecules of fundamental therapeutic value.
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![Aptamers as delivery agents. Aptamers that bind to cell surface receptors can be used to deliver siRNA to target cells.](pharmaceuticals-04-01434f1){#f1-pharmaceuticals-04-01434}

![Anti-PSMA aptamer-siRNA chimeras. (**a**) The RNA duplex and RNA aptamers are chemically conjugated with biotin. Thus, two biotinylated siRNAs and two aptamers are non-covalently assembled via streptavidin; (**b**) The 3′ end of the aptamer is extended to contain the nucleotide sequence that is complementary to the antisense strand of the siRNA, and the chimera is formed by annealing the aptamer to the siRNA antisense strand; (**c**) optimized chimeras in which the aptamer portion of the chimera is truncated, and the sense and antisense strands of the siRNA portion are swapped. A two-nucleotide 3′-overhang and a PEG tail are added to the chimera; (**d**) the 3′-terminus of the aptamer is conjugated to the sense strand of the siRNA, followed by a 10-mer loop sequence and then by the antisense strand of the siRNA.](pharmaceuticals-04-01434f2){#f2-pharmaceuticals-04-01434}

###### 

siRNAs and aptamers in clinical trials.

                         **Name**                              **Company**                                **Target (s)**                                                        **Therapeutic Indication**   **Clinical Stage**
  ---------------------- ------------------------------------- ------------------------------------------ --------------------------------------------------------------------- ---------------------------- --------------------
  **siRNAs**             TD101                                 Pachyonychia Congenita Project             Keratin 6A N171K mutant                                               Pachyonychia congenita       Phase I
  QPI-1007               Quark Pharmaceuticals                 Caspase 2                                  Non-arteritic anterior ischaemic optic neuropathy                     Phase I                      
  AGN211745              Sirna Therapeutics                    VEGFR1                                     AMD Choroidal neovascularization                                      Phase II                     
  PF-655                 Quark                                 RTP801                                     Diabetic macular oedema (DME), AMD                                    Phase I                      
  SYL040012              Sylentis                              β2 adrenergic receptor                     Glaucoma                                                              Phase II                     
  CEQ508                 MDRNA                                 β-catenin                                  Familial adenomatous polyposis                                        Phase I                      
  ALN-PLK1               Alnyam Pharmaceuticals                PLK1                                       Liver tumours                                                         Phase I                      
  FANG                   Gradalis                              Furin                                      Solid tumours                                                         Phase II                     
  CALAA-01               Calando Pharmaceuticals               RRM2                                       Solid tumours                                                         Phase I                      
  SPC2996                Santaris Pharm.                       BCL-2                                      Chronic myeloid leukaemia                                             Phase II                     
  ALN-VSP02              Alnylam Pharmaceuticals               VEGF, kinesin spindle protein              Solid tumours                                                         Phase I                      
  NCT00672542            Duke University                       LMP2, LMP7, and MECL1                      Metastatic melanoma                                                   Phase I                      
  Atu027                 Silence Therapeutics                  PKN3                                       Advanced, recurrent or metastatic solid malignancies                  Phase I                      
  QPI-1002/I5NP          Quark Pharmaceuticals                 p53                                        Acute kidney injury                                                   Phase II                     
  TKM-ApoB               Tekmira Pharmaceuticals Corp.         APOB                                       Hypercholesterolaemia                                                 Phase I                      
  PRO-040,201            Tekmira Pharmaceuticals Corp.         APOB                                       Hypercholesterolaemia                                                 Phase I                      
  SPC3649                Santaris Pharma                       miR-122                                    Hepatitis C virus                                                     Phase II                     
  pHIV7-shI-TAR-CCR5RZ   City of Hope Medical Center/Benitec   HIV Tat protein, HIV TAR RNA, human CCR5   HIV                                                                   Phase 0                      
  ALN-RSV01              Alnylam Pharmaceuticals               RSV nucleocapsid                           RSV in volunteers                                                     Phase II                     
  **Aptamers**           Macugen (Pegaptanib)                  Eyetech Pharmaceuticals/Pfitzer            VEGF-165                                                              AMD Diabetc retinopathy      Approved Phase III
  E10030                 Ophthotech Corp./Archemix Corp.       PDGF-B                                     AMD                                                                   Phase II                     
  ARC1905                Ophthotech Corp./Archemix Corp.       C5                                         AMD                                                                   Phase I                      
  ARC1779                Archemix Corp.                        vWF                                        TMA                                                                   Phase II                     
  NU172                  ARCA Biopharma/Archemix Corp.         Thrombin                                   Acute coronary artery bypass surgery                                  Phase II                     
  REG-1 (RB006/RB007)    Regado Biosciences/Archemix Corp.     Factor IXa                                 Percutaneous coronary intervention                                    Phase II                     
  NOX-A12                NOXXON Pharma                         SDF-1α                                     Lymphoma patients (undergoing autologous stem cell transplantation)   Phase I                      
  NOX-E36                NOXXON Pharma                         CCL2                                       Type 2 diabetes and diabetic Nephropathy                              Phase I                      
  AS1411 (AGRO001)       Antisoma/Archemix Corp.               Nucleolin                                  AML                                                                   Phase II                     

###### 

Aptamers as delivery tools.

  **Aptamer composition**   **Target**   **Cargos/targeted delivery**                              **Therapeutic Indication**
  ------------------------- ------------ --------------------------------------------------------- ----------------------------
  RNA, 2′-F-Py              PSMA         siRNA, Toxin, QDs, nanoparticles and chemiotherapeutics   Prostate cancer therapy
                                                                                                   
  RNA, 2′-F-Py              gp120        siRNA                                                     HIV infection
                                                                                                   
  RNA, 2′-F-Py              CD4          siRNA                                                     HIV infection
                                                                                                   
  RNA                       EGFR         Au NPs                                                    Cancer
                                                                                                   
  DNA                       PTK7         Doxorubicin, Au-Ag NPs                                    Cancer
                                                                                                   
  DNA                       Mucin 1      QDs, photodynamic therapy agents                          Cancer
                                                                                                   
  DNA                       Nucleolin    QDs                                                       Cancer
